Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Obesity

Treatments: Drug: AZD4017; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01096004

D2060M00001

Details and patient eligibility

About

The primary purpose of this study is to investigate different methods to evaluate the effect of AZD4017 in adipose tissue after single and multiple doses of AZD4017 in abdominally obese but otherwise healthy subjects.

Enrollment: 15 patients

Sex: Male

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Provision of signed written and dated informed consent
• Have a body mass index (BMI) between 27 and 35 kg/m2
• Waist circumference of >102 cm

Exclusion criteria

• History of any clinical significant disease
• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product
• Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator

Trial design

15 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: AZD4017

2

Placebo Comparator group

Treatment:

Drug: Placebo